Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | CREBBP | Q92793 | 7/20 | 0.45 |
| ▸ | BRD4 | O60885 | 7/20 | 0.45 |
| ▸ | EP300 | Q09472 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | TDO2 | P48775 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29990165 | 1.00 | ALDH1A1 (1.00) | ALDH1A1CREBBPBRD4EP300TSHR | |
| SCHEMBL1843998 | 1.00 | ALDH1A1 (1.00) | ALDH1A1CREBBPBRD4EP300TSHR | |
| SCHEMBL3919961 | 1.00 | ALDH1A1 (1.00) | ALDH1A1CREBBPBRD4EP300TSHR | |
| SCHEMBL30863319 | 1.00 | ALDH1A1 (1.00) | ALDH1A1CREBBPBRD4EP300TSHR | |
| SCHEMBL19953555 | 0.85 | ALDH1A1 (0.73) | ALDH1A1CREBBPBRD4EP300TSHR | |
| SCHEMBL13652133 | 0.83 | ALDH1A1 (0.71) | ALDH1A1MAPT | |
| SCHEMBL19960652 | 0.81 | ALDH1A1 (0.68) | ALDH1A1CREBBPBRD4EP300LMNA | |
| SCHEMBL11775988 | 0.80 | ALDH1A1 (0.67) | ALDH1A1CREBBPBRD4EP300TSHR | |
| SCHEMBL3912643 | 0.78 | ALDH1A1 (0.63) | ALDH1A1MAPTIDO1 | |
| SCHEMBL15897160 | 0.78 | ALDH1A1 (0.63) | ALDH1A1LMNAIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090247577-A1 | PYRROLIDINE DERIVATIVES USEFUL AS BACE INHIBITORS | ROGEL OLIVIER | 2009-10-01 | — | — | US | claimed |
| EP-2029544-A1 | PYRROLIDINE DERIVATIVES USEFUL AS BACE INHIBITORS | Novartis AG (CH) | 2009-03-04 | — | — | EP | claimed |
| WO-2007140980-A1 | PYRROLIDINE DERIVATIVES USEFUL AS BACE INHIBITORS | NOVARTIS AG (CH) | 2007-12-13 | — | — | WO | claimed |
| CN-117916231-A | Compounds for inhibiting or degrading target proteins, compositions comprising the same, methods of making and methods of using the same | 纽力克斯治疗公司 | 2024-04-19 | — | — | CN | disclosed |
| EP-4334302-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING TARGET PROTEINS, COMPOSITIONS, COMPRISING THE SAME, METHODS OF THEIR MAKING, AND METHODS OF THEIR USE | Nurix Therapeutics, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| US-20230158151-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING TARGET PROTEINS, COMPOSITIONS, COMPRISING THE SAME, METHODS OF THEIR MAKING, AND METHODS OF THEIR USE | NURIX THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230158151-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING TARGET PROTEINS, COMPOSITIONS, COMPRISING THE SAME, METHODS OF THEIR MAKING, AND METHODS OF THEIR USE | NURIX THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230158151-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING TARGET PROTEINS, COMPOSITIONS, COMPRISING THE SAME, METHODS OF THEIR MAKING, AND METHODS OF THEIR USE | NURIX THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| WO-2022235698-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING TARGET PROTEINS, COMPOSITIONS, COMPRISING THE SAME, METHODS OF THEIR MAKING, AND METHODS OF THEIR USE | NURIX THERAPEUTICS, INC. (US) | 2022-11-10 | — | — | WO | disclosed |
| US-20090247577-A1 | PYRROLIDINE DERIVATIVES USEFUL AS BACE INHIBITORS | ROGEL OLIVIER | 2009-10-01 | — | — | US | disclosed |
| EP-2029544-A1 | PYRROLIDINE DERIVATIVES USEFUL AS BACE INHIBITORS | Novartis AG (CH) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007140980-A1 | PYRROLIDINE DERIVATIVES USEFUL AS BACE INHIBITORS | NOVARTIS AG (CH) | 2007-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247577-A1 | PYRROLIDINE DERIVATIVES USEFUL AS BACE INHIBITORS | BACE1, BACE2, APP | ALDH1A1 1523/4885CREBBP 2474/4885BRD4 285/4885 |
| US-20230158151-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING TARGET PROTEINS, COMPOSITIONS, COMPRISING THE SAME, METHODS OF THEIR MAKING, AND METHODS OF THEIR USE | MDM2, XIAP, ADRM1 | ALDH1A1 3345/4885CREBBP 735/4885BRD4 332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.